Literature DB >> 24166497

Oncoprotein stabilization in brain tumors.

S-M Hede1, V Savov1, H Weishaupt1, O Sangfelt2, F J Swartling1.   

Abstract

Proteins involved in promoting cell proliferation and viability need to be timely expressed and carefully controlled for the proper development of the brain but also efficiently degraded in order to prevent cells from becoming brain cancer cells. A major pathway for targeted protein degradation in cells is the ubiquitin-proteasome system (UPS). Oncoproteins that drive tumor development and tumor maintenance are often deregulated and stabilized in malignant cells. This can occur when oncoproteins escape degradation by the UPS because of mutations in either the oncoprotein itself or in the UPS components responsible for recognition and ubiquitylation of the oncoprotein. As the pathogenic accumulation of an oncoprotein can lead to effectively sustained cell growth, viability and tumor progression, it is an indisputable target for cancer treatment. The most common types of malignant brain tumors in children and adults are medulloblastoma and glioma, respectively. Here, we review different ways of how deregulated proteolysis of oncoproteins involved in major signaling cancer pathways contributes to medulloblastoma and glioma development. We also describe means of targeting relevant oncoproteins in brain tumors with treatments affecting their stability or therapeutic strategies directed against the UPS itself.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166497     DOI: 10.1038/onc.2013.445

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  PTPN12/PTP-PEST Regulates Phosphorylation-Dependent Ubiquitination and Stability of Focal Adhesion Substrates in Invasive Glioblastoma Cells.

Authors:  Zhihua Chen; John E Morales; Paola A Guerrero; Huandong Sun; Joseph H McCarty
Journal:  Cancer Res       Date:  2018-05-09       Impact factor: 12.701

Review 2.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

Review 3.  The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.

Authors:  Jerry Vriend; Saeid Ghavami; Hassan Marzban
Journal:  Mol Brain       Date:  2015-10-17       Impact factor: 4.041

4.  Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.

Authors:  Sara Bolin; Anna Borgenvik; Camilla U Persson; Anders Sundström; Jun Qi; James E Bradner; William A Weiss; Yoon-Jae Cho; Holger Weishaupt; Fredrik J Swartling
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

5.  FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.

Authors:  Aldwin Suryo Rahmanto; Vasil Savov; Andrä Brunner; Sara Bolin; Holger Weishaupt; Alena Malyukova; Gabriela Rosén; Matko Čančer; Sonja Hutter; Anders Sundström; Daisuke Kawauchi; David Tw Jones; Charles Spruck; Michael D Taylor; Yoon-Jae Cho; Stefan M Pfister; Marcel Kool; Andrey Korshunov; Fredrik J Swartling; Olle Sangfelt
Journal:  EMBO J       Date:  2016-09-13       Impact factor: 11.598

6.  Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development.

Authors:  Giulia Gentile; Manuela Ceccarelli; Laura Micheli; Felice Tirone; Sebastiano Cavallaro
Journal:  Front Pharmacol       Date:  2016-11-30       Impact factor: 5.810

7.  Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy.

Authors:  Matko Čančer; Sonja Hutter; Karl O Holmberg; Gabriela Rosén; Anders Sundström; Jignesh Tailor; Tobias Bergström; Alexandra Garancher; Magnus Essand; Robert J Wechsler-Reya; Anna Falk; Holger Weishaupt; Fredrik J Swartling
Journal:  Cell Stem Cell       Date:  2019-11-27       Impact factor: 24.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.